ViroMed Receives Approval of Phase II Trial for Peripheral Artery Disease Drug

ViroMed has announced that VM202-PAD, a Deoxyribonucleic Acid (DNA) medicine for the treatment of Peripheral Artery Disease (PAD), has received approval from the US Food and Drug Administration (FDA) for a Phase II clinical trial. The trial will be performed under the supervision of the Principal Investigator, Dr Timothy Henry of Minneapolis Heart Institute.

Seven other hospitals and medical centers will also be involved in the recruitment and treatment of patients with PAD. The drug is designed to treat the fundamental causes of PAD.